OMER Omeros Corporation

15.86
+0.46  (+3%)
Previous Close 15.4
Open 15.34
Price To Book -6.01
Market Cap 781,701,288
Shares 49,287,597
Volume 392,797
Short Ratio
Av. Daily Volume 438,221
Stock charts supplied by TradingView

NewsSee all news

  1. Product-Specific J-Code for Omeros' OMIDRIA® is Now in Effect

    Omeros Corporation (NASDAQ:OMER) today announced that the product-specific J-code for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros' commercial drug marketed

  2. Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System's Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria

    Omeros Corporation (NASDAQ:OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria

  3. Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction

    -- Phase 1 study results show excellent safety and PK profile consistent with once-daily dosing -- Omeros Corporation (NASDAQ:OMER) today announced positive results from its Phase 1 study with the lead compound in its

  4. FDA Confirms Omeros' Schedule for Rolling Review of the Company's BLA for Narsoplimab in the Treatment of HSCT-TMA

    – Omeros Remains On Track to Initiate the Submission Next Quarter – Omeros Corporation (NASDAQ:OMER) announced that the United States Food and Drug Administration (FDA) agreed with the company's proposed schedule for

  5. Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174

    -- The Company's GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold -- Omeros Corporation (NASDAQ:OMER) today announced a new approach to cancer immunotherapy that targets

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling BLA filing to commence 4Q 2019.
OMS721
Hematopoietic stem cell-associated TMA (HSCT-TMA)
Phase 3 trial enrollment initiated February 2018. Continues to enrol as of August 2019.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)
Phase 1 data September 16, 2019 noted treatment was safe and well-tolerated.
OMS527
Nicotine Addiction

Latest News

  1. Product-Specific J-Code for Omeros' OMIDRIA® is Now in Effect

    Omeros Corporation (NASDAQ:OMER) today announced that the product-specific J-code for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros' commercial drug marketed

  2. Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System's Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria

    Omeros Corporation (NASDAQ:OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria

  3. Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction

    -- Phase 1 study results show excellent safety and PK profile consistent with once-daily dosing -- Omeros Corporation (NASDAQ:OMER) today announced positive results from its Phase 1 study with the lead compound in its

  4. FDA Confirms Omeros' Schedule for Rolling Review of the Company's BLA for Narsoplimab in the Treatment of HSCT-TMA

    – Omeros Remains On Track to Initiate the Submission Next Quarter – Omeros Corporation (NASDAQ:OMER) announced that the United States Food and Drug Administration (FDA) agreed with the company's proposed schedule for

  5. Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174

    -- The Company's GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold -- Omeros Corporation (NASDAQ:OMER) today announced a new approach to cancer immunotherapy that targets

  6. Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Omeros Corporation (NASDAQ:OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York next